Navigation Links
A novel in vitro model for light-induced wound healing
Date:3/4/2010

Washington, DC, USA Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher C. Millan (U.S. Army Dental Corps, Martinez, Georgia) will present a poster of a study titled "A Novel In Vitro Model for Light-Induced Wound Healing." Studies have suggested that exposure to minimal doses of blue-violet light (400-500 nm) elicits production of small amounts of reactive oxygen species (ROS), and contributes to increased mitochondrial activity and cell growth in epithelial cells. Many growth factor signaling pathways generate ROS.

In this study, Millan and other researchers involved in this study hypothesize that exposure to blue-violet light may enhance cell growth. To test this hypothesis, they developed a novel in-vitro wound healing model that allowed them to monitor the cellular responses to a single, small dose of light in cultured cells.

Normal human epidermal keratinocytes (NHEK) and human gingival fibroblasts (HGF) were plated around cloning cylinders. At confluency, the cylinders were removed to create a wound. Cells were treated with a single 5 J/cm2 light dose delivered by a quartz-tungsten-halogen light source. Mitochondrial succinate dehydrogenase activity was measured via a standard MTT assay, and cell proliferation was assessed using DRAQ5 DNA dye. Conditioned media were collected at each time point and used in a growth factor antibody array (RayBio) to compare the secretion products.

Growth factor array results showed that NHEK responded to blue light exposure by increasing secretion of several growth factors including insulin-like growth factor binding protein-1, amphiregulin, epidermal growth factor and fibroblast growth factor-b. Likewise, mitochondrial dehydrogenase activity and cell proliferation were enhanced in NHEK. In contrast, HGF did not respond to blue light exposure significantly in any of the parameters tested.

These results show that NHEK cells responded robustly to a single, small dose of light by increasing their mitochondrial activity, DNA synthesis, and production of growth factors. Together, these data suggest that blue light may be useful to enhance epithelial cell growth in a wound site.


'/>"/>

Contact: Ingrid Thomas
ithomas@aadronline.org
703-299-8084
International & American Association for Dental Research
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small ... the National Institutes of Health (NIH) to ... University.  The grant will seek to ... head device, which utilizes electromagnetic waves to treat Alzheimer,s ... this novel technology to possibly treat other neurologic disorders ...
Breaking Medicine Technology: